Lyophilized live attenuated Salmonella Enteritidis API intended for mass oral vaccination of commercial layer and broiler flocks via drinking water represents one of the most process-sensitive downstream formats in veterinary biologics manufacturing. The pre-lyophilization formulation consists of a stabilizer matrix combining 4–8% w/v sucrose, 1–2% w/v gelatin, and 1–2% w/v sorbitol in 10 mM potassium phosphate buffer pH 7.0–7.4, with the viable antigen adjusted to 1×10⁸–5×10⁸ CFU per single fowl dose before freeze-drying. Production-scale lyophilisation is executed in multi-shelf dryers with shelf temperature ramps from −45 °C to +20 °C over 28–36 h, chamber pressure held at 50–200 µbar, and primary drying governed by a product temperature not exceeding −20 °C to prevent cake collapse. Residual moisture is controlled to 1.5–3.0% by semi-micro determination per Ph. Eur. 2.5.12, and post-reconstitution viability must not decline more than 0.5 log relative to pre-lyophilization counts when reconstituted in cold potable water. Process failures recorded on production lines include edge-vial collapse when shelf temperature uniformity exceeds ±2 °C and viability loss greater than 1 log when condenser capacity is undersized for the batch load. The terminal dosage form is a lyophilized cake or free-flowing powder in glass vials for reconstitution as a drinking-water suspension. Compliance assessment is anchored to Ph. Eur. 0062 Vaccines for Veterinary Use, Ph. Eur. 5.2.6 Evaluation of Efficacy of Veterinary Vaccines, Ph. Eur. 5.2.7 Safety of Veterinary Vaccines, and Ph. Eur. 2.6.1 Sterility. Addition rates for chlorine-neutralised drinking water are typically 1 dose per bird per administration, with the reconstituted suspension used within 2 h because potable water residual chlorine above 0.3 ppm reduces viable count by 0.4–0.6 log in field conditions.

How Does Oil-in-Water Emulsion Stability Govern Inactivated Salmonella Enteritidis Vaccine Efficacy in Broiler Breeders?

Formalised Salmonella Enteritidis whole-cell antigen is prepared at 1×10⁹ inactivated cells/mL in the aqueous phase, which constitutes 30% v/v of the final emulsion; the oil phase, 70% v/v, consists of light mineral oil containing 1–2% w/v Arlacel 80 as a non-ionic lipophilic emulsifier. A production-scale high-shear rotor-stator mixer operated at 10,000 ± 500 rpm for 5–10 min generates a droplet size distribution with Dv50 of 1–3 µm, measured by laser diffraction per ISO 13320:2009. Batch-to-batch variation in Dv90 beyond 8 µm correlates with accelerated creaming and injection-site granuloma formation in field lots, establishing Dv90 as a batch release criterion. Viscosity is maintained at 25–50 mPa·s at 25 °C per Ph. Eur. 2.2.8 to permit passage through 18–21 G needles without excessive syringe force. Residual formaldehyde after inactivation is reduced to ≤0.1% w/v by diafiltration through 100 kDa tangential flow membranes, and thiomersal is added at 0.01% w/v as preservative. The downstream process includes inactivation at 37 °C for 24 h, removal of low-molecular-weight medium components, emulsification, and aseptic filling into 500 mL bottles. The terminal product is an oil-emulsion injectable suspension administered intramuscularly at 0.5 mL per bird. Compliance testing follows Ph. Eur. 0062, Ph. Eur. 5.2.7, and Ph. Eur. 2.6.15 Bacterial Endotoxins; published data for emulsion ageing in this specific antigen configuration is limited but industrial lot records support droplet size and viscosity as primary release criteria. Storage at 2–8 °C is mandatory because freeze-thaw cycles split the emulsion, releasing free aqueous antigen and reducing potency below the reference titre.

Swine oral live attenuated Salmonella Typhimurium API formulated as enteric-coated granules for feed top-dressing requires a two-step fluid-bed process. First, the antigen is adsorbed onto a carrier blend of 70–80% w/w lactose monohydrate and 10–15% w/w microcrystalline cellulose; second, a methacrylic acid copolymer dispersion, Eudragit L 30 D-55, is sprayed at 12–18% dry weight gain in a Wurster insert with inlet air temperature 35–40 °C, product temperature not exceeding 28 °C, and outlet relative humidity below 30%. The final granule contains 2×10⁹ CFU/g, and inclusion in feed at 1 kg premix per tonne delivers approximately 1×10⁸ CFU per animal per day to grow-finish pigs. Loss on drying is held at <3%, and acid resistance testing in pH 1.2 HCl for 2 h followed by pH 6.8 phosphate buffer for 1 h must show release of more than 80% of viable organisms. Particle size distribution is controlled by sieve analysis per Ph. Eur. 2.9.38, with granules retained between 250 µm and 1.4 mm to ensure feed distribution uniformity. Process failure modes observed at production scale include irreversible viability loss when inlet air exceeds 45 °C and electrostatic agglomeration of granules when relative humidity falls below 10%. Tablet and capsule formats are uncommon for mass oral vaccination because the required CFU dose cannot be reliably delivered under field feeding conditions, and published data for compressed-tablet antigen survival during direct compression at 5–15 kN hardness is insufficient to define release criteria. The terminal product is a granulated premix for oral administration; compliance is evaluated under Ph. Eur. 0062, Ph. Eur. 5.2.6, and VICH GL44 Target Animal Safety for Veterinary Live and Inactivated Vaccines.

Aluminium Hydroxide-Adsorbed Salmonella Typhimurium Bacterin for Parenteral Use in Swine

Killed whole-cell Salmonella Typhimurium antigen is produced in tryptic soy broth to 1×10¹⁰ cells/mL, inactivated with 0.5% v/v formalin at 37 °C for 48 h, then concentrated and diafiltered through 100 kDa tangential flow membranes. Adsorption to Alhydrogel 2% aluminium hydroxide gel is conducted at 4 °C for 4–8 h with continuous stirring, targeting 2.0 mg Al per 2 mL dose and 95% antigen adsorption at pH 6.8–7.2. The buffer system is 10 mM phosphate with 0.85% sodium chloride and 0.01% thiomersal as preservative. Critical process limitations include precipitation when pH drifts above 7.4 and irreversible gel matrix aggregation if storage drops below 0 °C. Terminal product is an injectable suspension administered intramuscularly at 2 mL per swine, with release testing per Ph. Eur. 0062, Ph. Eur. 5.2.6, and Ph. Eur. 2.6.14 Pyrogens. Batch-to-batch variance in adsorption efficiency is monitored by centrifugation followed by total protein assay per Ph. Eur. 2.5.33, and free antigen exceeding 5% triggers formulation rework. The formulation is not compatible with lyophilisation because aluminium hydroxide gel particles sediment and aggregate during freeze-thaw cycles, producing visible flocculation and failure of syringeability tests using 18 G needles. Production-scale observations indicate that addition of antigen to aluminium hydroxide under high-shear mixing above 500 rpm reduces adsorption by 10–15 percentage points, whereas low-shear magnetic stirring at 100–200 rpm preserves the gel structure and achieves consistent adsorption kinetics within 2 h.

When Salmonella Dublin Bacterin Is Combined with Clostridial Toxoids in Dairy Calf Vaccination Programs

Formulation of Salmonella Dublin formalinised bacterin at 1×10⁹ cells/mL with aluminium hydroxide adjuvant at 2.5 mg Al per dose and pH 6.5–7.0 supports simultaneous subcutaneous administration with Clostridium perfringens type C and D toxoids in dairy calves from 2 weeks of age. The blending sequence requires separate adjuvant adsorption for each antigen before final combination, preventing competitive displacement from the aluminium hydroxide surface; batch records from multi-valent production lines document that sequential addition reduces free antigen below 5% as measured by centrifugation and UV absorbance at 280 nm per Ph. Eur. 2.2.25. Final dosage is 2 mL subcutaneously, with a booster at 21–28 days. Process incompatibilities include elevated endotoxin burden if formaldehyde concentration exceeds 0.2% v/v during inactivation, and gel particle aggregation when calcium-containing diluents are used for reconstitution or dilution. The terminal product is an injectable suspension; compliance is assessed according to Ph. Eur. 0062, Ph. Eur. 5.2.6, and Ph. Eur. 2.6.14 Pyrogens. Shelf-life data from production lots indicate that aluminium hydroxide adjuvant particle size Dv50 increases from 1.5 µm to 4.8 µm over 18 months at 2–8 °C, necessitating gentle resuspension by hand shaking for 20–30 s before each use. Vaccination of animals with concurrent colostral antibody levels above 1.5 log₁₀ neutralising titre may suppress seroconversion to the bacterin, a limitation documented in field efficacy studies conducted under VICH GL44.

Hatchery spray administration of live attenuated Salmonella Typhimurium vaccine for day-old chicks uses a water-based solution prepared by dissolving a lyophilized powder in sterilised distilled water to 1×10⁹ CFU/mL concentrate, then diluting 1:10 to yield 1×10⁸ CFU per 0.5 mL dose. Skim milk powder at 5% w/v acts as a stabiliser against mechanical stress in spray nozzles, and the final solution pH is adjusted to 6.8 with sodium bicarbonate; chlorine neutralisation with 0.1% sodium thiosulfate is mandatory when using potable water. Spray equipment includes cabinet sprayers with flat-fan nozzles generating droplet sizes of 100–200 µm; nozzle blockage from undissolved powder aggregates larger than 20 µm is eliminated by in-line filtration through 20 µm nylon mesh. Terminal product is a solution for use within 2 h after reconstitution, with no preservative system because sodium thiosulfate would interfere with viability if present above 0.15%. Compliance is established under Ph. Eur. 0062 and Ph. Eur. 5.2.6; pH is measured per Ph. Eur. 2.2.3 and sterility per Ph. Eur. 2.6.1. Field-scale failures include uneven droplet distribution when cabinet relative humidity exceeds 70%, causing wetting of chick down and reduced preening-mediated ingestion. Published data for this specific configuration is limited, but production records indicate that spray vaccination achieves uniform flock coverage only when the target droplet size is maintained within ±20 µm of the 150 µm design point.